Foiu 2018: Should The Primary Be Treated In Patients With Metastatic Disease | Latest News RSS feed

Foiu 2018: Should The Primary Be Treated In Patients With Metastatic Disease - Latest News

ASCO GU 2019: Efficacy and Safety Data of the ARAMIS Study, Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer Patients

San Francisco, CA ( The treatment landscape for non-metastatic castration-resistant prostate (nmCRPC) cancer is rapidly evolving. In 2018 ... the primary endpoint and radiographic imaging ... read more

Phase 3 ARCHES Trial Shows Xtandi Significantly Improved Radiographic Progression-Free Survival in Men with mHSPC

The results show that XTANDI ® (enzalutamide) plus androgen deprivation therapy (ADT) met the primary endpoint ... and subsequently developed metastatic disease. The trial also included some patients ... read more

Priority Review Designation in TGCT, BLA Submitted in HER2+ Breast Cancer, and More

Moreover, the 3-year invasive disease ... for the treatment of patients with metastatic HER2-positive breast cancer who previously received trastuzumab and a taxane, either alone or in combination. Th... read more

Looking for another news?

'Remarkable' New Benefit in HER2+ Breast Cancer

The treatment ... primary breast cancer (clinical tumor stage T1 to T4, nodal stage N0 to N3, and metastasis stage M0). In other efficacy data from the trial, distant recurrence (metastatic disease) a... read more

Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide)…

In the placebo-controlled study of non-metastatic CRPC (nmCRPC) patients, Grade 3 or higher adverse reactions were reported in 31% of XTANDI patients and 23% of placebo patients. Discontinuations with ... read more

Asia’s Scientific Trailblazers: Bang Yung-Jue

Globally, one in five men and one in six women will be diagnosed with the dreadful disease in ... before a main treatment) or adjuvant (adjunct or add-on) treatment of previously untreated patients wi... read more

Osimertinib shows 'consistent improvement' in post-progression endpoints for non-small cell lung cancer

Patients had EGFR-mutated, locally advanced, metastatic ... of disease progression and known T790M-positive mutation. PFS served as the study’s primary endpoint. Exploratory post-progression endpoints ... read more

ASCO GU 2019: Multimodality Treatment in Challenging Cases of Urothelial Carcinoma: Case Panel Discussion

EU 2018) is a new ... radiation for patients with metastatic UC after resection of primary tumor demonstrated that patients with single node positive did best. Of 22 patients, 8 had long-term survival ... read more

TYME Reports Third Quarter Fiscal 2019 Financial and Operating Results

“Pancreatic Cancer is a devastating disease ... funding and patient support for this investigator-initiated Phase II (HopES) trial of SM-88 in patients with previously-treated metastatic ... read more

Adjuvant Docetaxel No Help in High-Risk Prostate Cancer

Based on these results, "docetaxel may not be as suitable in a high-risk setting as in a metastatic ... patients could see "early evolution to AR independence." In general, however, he noted that adju... read more

FDA Recommends No NDA for Tivozanib in RCC

Those who received prior therapy with sorafenib or tivozanib; received more than 3 prior regimens for their metastatic disease ... primary malignancy were excluded. The European Commission approved ti... read more

FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us